These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17031283)

  • 21. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
    Chen CY; Wong TY; Heriot WJ
    Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].
    Mackiewicz J; Mańkowska A; Dolar-Szczasny J; Zubilewicz A; Oleszczuk A; Nowomiejska K; Rejdak R; Zagórski Z
    Klin Oczna; 2007; 109(4-6):146-9. PubMed ID: 17725273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A very effective treatment for neovascular macular degeneration.
    Stone EM
    N Engl J Med; 2006 Oct; 355(14):1493-5. PubMed ID: 17021326
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avastin in myopic choroidal neovascularisation: is age the limit?
    Wong D; Li KK
    Br J Ophthalmol; 2008 Aug; 92(8):1011-2. PubMed ID: 18653589
    [No Abstract]   [Full Text] [Related]  

  • 31. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiangiogenic therapy].
    Arias Barquet L
    Arch Soc Esp Oftalmol; 2005 Aug; 80(8):435-6. PubMed ID: 16136393
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antiangiogenic therapy for choroidal neovascularization induced by age-related macular degeneration (preliminary communication)].
    Avetisov SE; Mamikoian VR; Surguch BK; Sdobnikova SV
    Vestn Oftalmol; 2009; 125(6):3-8. PubMed ID: 20143531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
    Tewari A; Dhalla MS; Apte RS
    Retina; 2006; 26(9):1093-4. PubMed ID: 17151505
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
    Kimmelman J
    Retina; 2007; 27(9):1166-7. PubMed ID: 18046219
    [No Abstract]   [Full Text] [Related]  

  • 37. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks.
    Teixeira A; Moraes N; Farah ME; Bonomo PP
    Acta Ophthalmol Scand; 2006 Dec; 84(6):835-6. PubMed ID: 17083556
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
    Laud K; Spaide RF; Freund KB; Slakter J; Klancnik JM
    Retina; 2006 Oct; 26(8):960-3. PubMed ID: 17031300
    [No Abstract]   [Full Text] [Related]  

  • 39. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.
    Carneiro AM; Silva RM; Veludo MJ; Barbosa A; Ruiz-Moreno JM; Falcão MS; Brandão EM; Falcão-Reis FM
    Ophthalmologica; 2011; 225(2):81-8. PubMed ID: 20881442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.